Dr. Ronald Farkas, a leading critic against Sarepta Therapeutics Inc.'s (SRPT) eteplirsen, has reportedly left the FDA for another employment opportunity. The drug is a potential treatment for the genetic disease Duchenne muscular dystrophy.
from RTT - Before the Bell http://ift.tt/2cpHots
via IFTTT
No comments:
Post a Comment